Indegene Ltd
It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.
- Market Cap ₹ 13,616 Cr.
- Current Price ₹ 569
- High / Low ₹ 660 / 469
- Stock P/E 98.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 20.4 %
- ROE 15.8 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 19.6%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 282 | 334 | 511 | 837 | 1,006 | 1,046 | |
| 230 | 249 | 361 | 668 | 828 | 878 | |
| Operating Profit | 53 | 86 | 150 | 169 | 178 | 168 |
| OPM % | 19% | 26% | 29% | 20% | 18% | 16% |
| 12 | -24 | 30 | 28 | 37 | 50 | |
| Interest | 1 | 3 | 4 | 3 | 6 | 7 |
| Depreciation | 4 | 13 | 18 | 24 | 32 | 31 |
| Profit before tax | 59 | 46 | 159 | 170 | 177 | 181 |
| Tax % | 14% | 30% | 17% | 22% | 26% | 24% |
| 51 | 32 | 132 | 133 | 130 | 138 | |
| EPS in Rs | 324.22 | 202.30 | 843.58 | 755.26 | 5.87 | 6.20 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 27% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 2% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 20% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 0 | 0 | 44 | 44 |
| Reserves | 158 | -3 | 254 | 650 | 751 | 909 |
| 106 | 362 | 23 | 44 | 51 | 38 | |
| 57 | 72 | 96 | 156 | 191 | 228 | |
| Total Liabilities | 322 | 431 | 373 | 850 | 1,038 | 1,220 |
| 8 | 31 | 41 | 72 | 78 | 56 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | 134 | 251 | 83 | 203 | 400 | 624 |
| 180 | 148 | 249 | 575 | 559 | 540 | |
| Total Assets | 322 | 431 | 373 | 850 | 1,038 | 1,220 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 62 | 90 | 53 | 38 | 82 | 176 | |
| -70 | -51 | -34 | -267 | -51 | -188 | |
| 15 | -18 | -37 | 245 | -17 | -16 | |
| Net Cash Flow | 8 | 20 | -18 | 16 | 14 | -27 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 65 | 65 | 125 | 152 | 145 | 129 |
| Inventory Days | ||||||
| Days Payable | ||||||
| Cash Conversion Cycle | 65 | 65 | 125 | 152 | 145 | 129 |
| Working Capital Days | 51 | 21 | 84 | 107 | 118 | 192 |
| ROCE % | 28% | 49% | 36% | 24% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
11 Jul - Press release dated July 11, 2024 titled ''Indegene Announces Strategic Collaboration with Microsoft to Help Life Sciences Companies Scale Up Generative AI Adoption and Accelerate …
- Closure of Trading Window 28 Jun
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
24 Jun - Officials of the Company will be meeting Investor / Analyst
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Jun - Of Schedule of Investor / Analyst meeting under the SEBI (LODR), Regulations, 2015
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Jun - Of Schedule of Investor / Analyst meeting under the SEBI (LODR), Regulations, 2015
Concalls
-
Jun 2024TranscriptPPTREC
Business Divison[1]
A) Enterprise Commercial Solutions aids life science companies in optimizing digital marketing operations, driving scale efficiency, and implementing technology-enabled personalization strategies for engagement with HCPs, patients, and operations.